Effect of prolonged uremia on insulin metabolism by isolated liver and muscle  by Rabkin, Ralph et al.
Kidney International, Vol. 16 (1979), pp. 433-439
Effect of prolonged uremia on insulin metabolism by isolated
liver and muscle
RALPH RABKIN, STEFAN A. UNTERHALTER, and WILLIAM C. DUCKWORTH
Department ofMedicine, University ofTennessee Centerfor the Health Sciences, and Departments of Medicine and
Research, Veterans Administration Hospital, Memphis, Tennessee
Effect of prolonged uremia on insulin metabolism by isolated
liver and muscle. As the prolonged metabolic clearance rate of
insulin in chronic uremia cannot be entirely explained by im-
paired removal and degradation of insulin by the kidney, we set
out to determine whether prolonged uremia depresses other ma-
jor sites of insulin degradation. The study was conducted with
livers and skeletal muscle obtained from normal control rats and
uremic rats 4 weeks after 80% nephrectomy. Despite a signifi-
cant difference between renal function in the control and uremic
rats (BUN, 18 vs. 46 mgldl), there was no significant difference in
the clearance of insulin by isolated uremic or control livers per-
fused with a bloodless medium. Similarly, the 1251—insulin de-
grading activity of liver homogenates was not depressed by ure-
mia. In contrast, binding and degradation by uremic liver cell
membranes was significantly reduced to 58% and 85% of the con-
trols, respectively. Degradation by homogenates of skeletal
muscle and by intact epitrochlaris muscle was significantly less
in uremics than in controls. These results indicate that chronic
uremia depresses skeletal muscle insulin degradation but not he-
patic insulin removal or degradation despite a decrease in insulin
binding and degradation by liver plasma membranes. It thus ap-
pears that depression of insulin degradation by muscle may con-
tribute to the prolonged insulin metabolic clearance rate seen in
chronic uremia. Furthermore, it is possible that the impaired
binding of insulin to liver membranes may play a role in the in-
sulin resistance of uremia.
Effet de l'urémie prolongee sur le métabolisme de l'insuline par
le muscle et le fole isolés. Puisque Ia diminution de Ia clearance
métabolique de l'insuline au cours de l'urémie ne peut pas être
entièrement expliquée par un deficit de captation et de degrada-
tion de linsuline par le rein, nous avons cherché une depression
par l'urémie de Ia degradation de l'insuline dans d'autres sites.
L'étude a été réalisée sur des foies et des muscles squelettiques
préleves sur des rats contrôles et des rats uremiques quatre se-
maines après une nephrectomie des 4/5. En dépit dune dif-
férence significative entre les fonctions rénales des contrôles et
des urérniques (azote urémique 18 et 46 mg/dl respectivenlent) il
n'a pas ete observe de difference significative de Ia clearance de
l'insuline dans les foies, contrôles ou urémiques, isolés, perfuses
avec un liquide dépourvu de sang. De Ia même facon Ia degrada-
tion de linsuline 'l par les homogenats de foie nest pas dé-
prlmee par l'uremie. Au contraire Ia liaison et Ia degradation par
les membranes cellulaires hépatiques de foies urémiques sont re-
spectivement diminuées de 58% et 85% des valeurs contrôles.
La degradation par des homogenats de muscle squelettique et
par du muscle epitrochleen intact est significativement inférieure
chez les uremiques. Ces résultats indiquent que l'urémie chro-
nique déprime Ia degradation de l'insuline par le muscle squellet-
tique mais pas La captation ou La degradation hepatique, celà
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malgré une diminution de Ia liaison et de la degradation par les
membranes hepatiques. II apparait done que la depression de la
degradation de linsuline par le muscle peut contribuer a La di-
minution de Ia clearance metabolique observée au cours de
lurémie. Ii est possible, de plus, que les modifications de Ia liai-
son de L'insuline aux membranes hepatiques joue un rOle dans Ia
résistance a l'insuline au cours de l'urémie.
In the presence of renal failure, the removal of
insulin from the circulation is impaired [I]. Para-
doxically, this is associated with carbohydrate in-
tolerance secondary to a resistance to the action of
insulin [2]. As the kidney is but one of several major
sites of insulin metabolism [3, 4], the possibility ex-
ists that in addition to the loss of renal tissue the
impaired removal of insulin in uremia may also be a
consequence of the effect of uremia on insulin me-
tabolism in other organs. If this hypothesis is cor-
rect, then it might be expected that dialysis would
improve the rate of insulin removal. Unfortunately,
studies in dialysis patients have yielded conflicting
results [5—7].
To determine whether prolonged uremia depress-
es other major sites of insulin removal, a study was
carried out with uremic rats 4 weeks after partial
(80%) nephrectomy and with normal rats as con-
trols. This model was chosen because in the rat,
prolonged loss of renal tissue of this degree is asso-
ciated with hyperinsulinemia and carbohydrate in-
tolerance as is seen in clinical uremia [8]. In our
study, we found that prolonged uremia did not im-
pair the removal of insulin by the isolated in situ
perfused liver or the degradation of i25I..iodo..insulin
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by liver homogenates. In contrast, degradation of
1251-iodo-insulin by skeletal muscle was impaired.
These findings suggest that the slow disappearance
of insulin in prolonged renal failure may be in part
due to the depression of insulin degradation in
muscle. Binding of '251-iodo-insulin to liver plasma
membranes was also examined and was found to be
impaired in the presence of prolonged uremia, sug-
gesting a potential explanation for the insulin resis-
tance of uremia.
Methods
Adult male Sprague-Dawley rats were used in all
the experiments. Two groups of animals were stud-
ied: normal control rats with two intact kidneys and
uremic rats with reduced renal mass. Renal in-
sufficiency was produced by surgical ablation of ap-
proximately 80% of the renal mass as described by
Muirhead et al [9]. With the rats under light pento-
barbital anesthesia, the right kidney was explored,
dissected free of surrounding tissue, then clamped
in a special device for holding the kidney and apply-
ing sutures. Sutures were then tied, and the two
poles of the kidney were severed, leaving the cen-
tral portion intact. The animals were then allowed
to recover from anesthesia, and 4 or 5 days later a
contralateral nephrectomy was performed under
pentobarbital anesthesia. Control and nephrecto-
mized rats were then placed on a daily diet of 20 g of
Purina rat chow (Ralston Purina Co., St. Louis,
Missouri) because in preliminary experiments when
rats were allowed free access to food, the controls
gained considerably more weight than did the ure-
mics. After 28 days, experiments were performed
following a 24-hour fast.
Liver perfusion. The livers of eight control and
seven uremic rats were isolated in situ and perfused
at 37° C according to the recirculation technique of
Hems et al [10]. After inducing anesthesia with pen-
tobarbital (60 mg/kg, i.p.), we opened the abdomi-
nal cavity, administered heparin (200 U, i.v.), and
cannulated the bile duct with a PE-lO catheter and
the portal vein with a polyethelene intravenous can-
nula. The thorax was then opened, PE-190 tubing
inserted into the inferior vena cava through the right
atrium, and the vena cava tied off below the liver.
Blood was flushed out of the liver with 20 ml of oxy-
genated Krebs-Henseleit-bicarbonate followed by
20 ml of perfusion medium, and the recycling per-
fusion commenced. The perfusion medium (80 ml),
previously filtered through a 0.45-M millipore fil-
ter, was oxygenated continuously with 95% oxygen
and 5% carbon dioxide, and the liver was perfused
at a pressure of 8 to 14 cm of water. The medium
consisted of Krebs-Henseleit-bicarbonate contain-
ing 2.5 m calcium chloride, 15 mri glucose, and
4% bovine serum albumin (Fraction V, Miles Labo-
ratories, Elkhart, Indiana); pH was adjusted to 7.4
with 1 M bicarbonate as required during the per-
fusion. Livers were used if there was no swelling of
the organ and if there was adequate and uniform
perfusion as evidenced by clearing of blood from
the organ and a good flow of bile. Perfusion flow
was determined from timed collections of hepatic
venous effluent and averaged 35 mllmin. To validate
the metabolic function of livers perfused in our lab-
oratory, we assessed the ability of five normal livers
perfused with a glucose-free medium to synthesize
glucose from saturating concentrations (10 mM) of
lactate.
After 25 mm of perfusion, highly purified porcine
insulin (Eli Lilly and Co., Indianapolis) was added
which produced an average insulin concentration of
approximately 26 ng/ml in the perfusate sample
taken 5 mm later. After a further 5 mm, a second
sample was taken; thereafter samples were ob-
tained at 10-mm intervals for 60 mm. The hepatic
clearance of insulin (in microliters per minute) was
calculated from the linear portion of the insulin dis-
appearance curve according to the method of Morti-
more, Tietze, and Stetten [11], as k = 2.3 V/st log
({C1 — C}/{C2 — C}), where k = hepatic clear-
ance, V = volume of perfusion fluid, C1 and C2 =
initial and final concentrations over the time inter-
val t, and C = asymptote approached by C after
prolonged perfusion. As preliminary experiments
with low concentrations of insulin indicated the
eventual disappearance of insulin after prolonged
perfusion, C was assumed to be zero. Results are
expressed as the mean and standard error of the
mean. Statistical analysis was made using Student's
t test for unpaired data. A P value of less than 0.05
was taken as being significant.
Preparation of muscle and liver homogenates
and liver plasma membranes. After an overnight
fast, control and uremic rats were killed by decapi-
tation. The hind leg muscles were removed,
cleansed of loose connective tissue, and homoge-
nized in 0.35 M sucrose, 5 ml/g of tissue, in a Waring
blender for 90 sec. The muscles from each animal
were kept separate. The homogenate was centri-
fuged for 15 mm at x 13,000 g, and the supernatant
was used for assay of insulin degrading activity.
Previous studies have shown that over 95% of the
insulin degrading activity of the homogenate is re-
covered in this fraction [12]. We have found also
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that the insulin degrading activity in homogenates
of hind limb and epitrochiaris muscle are the same.
Livers were removed from the animals and were
either homogenized in 0.35 M sucrose for sub-
cellular fractionation as described previously [13] or
in 0.001 M sodium bicarbonate for membrane prepa-
rations. Partially purified rat liver membranes were
prepared by the technique of Neville [14] as modi-
fled by Pohi, Birnbaumer, and Rodbell [15]. Mem-
brane protein was estimated by the method of Low-
ry et al [16]; and specific activity of the membrane
marker enzyme 5'-nucleotidase, by the method of
Song and Bondansky [17]. No difference was found
in the purity of the liver membrane preparation
from control and uremic rats as measured by the
activity of the marker 5'-nucleotidase (0.45 0.5
vs. 0.42 0.3 smoles of phosphate per milligram of
protein per minute, respectively).
Measurement of insulin degrading activity in ho-
mogenates. Insulin degrading activities of the ho-
mogenates and subcellular fractions thereof were
assayed by measuring the production of trichiorace-
tic acid (TCA) soluble materials from '251-mono-
iodo-insulin (Nuclear International, Burlington,
Massachusetts) as described previously [13]. The
assay consisted of incubating the tissue fraction
with 1251-iodo-insulin, 1 x 10'° M, in 0.05 M Tris
hydrochloric acid buffer (pH, 7.2) containing 0.5%
bovine serum albumin in a total volume of 1 ml at
370 C for 15 mm. The reaction was stopped by the
addition of I ml of 10% trichioracetic acid. After
centrifugation in an International refrigerated cen-
trifuge, the supernatants and precipitates were
counted in a Packard autogamma spectrometer, and
the percent degraded was calculated from the in-
crease in radioactivity present in the supernatant
over control tubes incubated without tissue frac-
tions. All tissue fractions were diluted so that the
maximal degradation in any assay never exceeded
10%.
Preparation of isolated epitrochiaris muscle and
assay of insulin degrading activity. Epitrochiaris
muscles were obtained by exposing the entire
muscle and freeing it from fascial attachments by
blunt dissection. The tendons were cut near their
insertions, and the intact muscle was removed in its
entirety. After being rinsed in isotonic sodium chlo-
ride, blotted, and weighed, the muscle was placed in
0.025 M Tris-Ringers buffer with 0.5% bovine serum
albumin (pH, 7.4). 1251-iodo-insulin (1 X 10b0 M)
was added, and the muscle was incubated at 37° C
for 15 mi Preliminary experiments demonstrated a
linear rate of degradation for at least 20 mm. At the
end of the incubation, duplicate 100-pi aliquots
were removed, and each was added to 0.9 ml of ice-
cold buffer, followed by TCA precipitation as be-
fore. Degradation was calculated as the net increase
in TCA-soluble radioactivity in tubes incubated
with muscle as compared with control tubes con-
taining only '251-iodo-insulin in buffer. In another
set of experiments one muscle from each animal
was preincubated for 15 mm at 37° C without 125J..
iodo-insulin and then transferred to fresh buffer
containing '251-iodo-insulin and incubated as de-
scribed above. The paired muscle from each animal
was incubated directly as described above.
Insulin membrane-binding and degrading assay.
The assay for binding to the cell membranes was
similar to that described by Freychet, Roth, and
Neville [18]. A typical assay consisted of 1251-la-
beled hormone (approximately 2 X 10-10 M), mem-
branes (0.4 mg of protein/ml), and unlabeled hor-
mone or other additions in 0.025 M Tris-Ringer's
buffer with 0.5% bovine serum albumin (pH, 7.4) in
a total volume of 300 l. After incubation at 30° C
(or as indicated) for the specified time, duplicate
100-pi aliquots were removed and added to micro-
fuge tubes containing 200 l of cold buffer. After
centrifugation at x l7,000g for 5 mm in the cold, the
supernate was removed and added to 0.05 M Tris
hydrochloric acid (pH, 7.2) containing 0.5% bovine
serum albumin, and then equal volumes of 10% tri-
chloracetic acid were added, and the percent of 1251
iodo-insulin degraded was determined. The mem-
brane precipitate was counted in a Packard auto-
gamma spectrometer.
Perfusate and blood measurements. Insulin was
assayed in perfusate samples by a modification of
the double antibody technique of Morgan and Laza-
row [19]. Bovine serum albumin was added to the
standards to provide the same protein concentra-
tion as in the perfusate samples. Blood urea nitro-
gen was measured with a Beckman BUN analyzer;
and glucose, by means of a glucose oxidase method
in a Beckman glucose analyzer.
Results
Renal function (Fig. 1). As measured by the BUN
concentration, renal insufficiency was pronounced
in the nephrectomized rats. In these uremic ani-
mals, BUN was 46 4.8 mg/dl, being significantly
higher than it was in the controls where BUN was
18 0.6 mgldl (P < 0.001).
Liver function. The average rate of gluconeogen-
esis in livers from normal rats perfused with 10 m'i
lactate was 0.81 0.09 moles/g of wet weight per
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minute, a value that does not differ significantly
from that obtained by others [10, 20].
Hepalic insulin clearance. The clearance of in-
sulin from the medium perfusing livers from control
and uremic animals is shown in Fig. 1. The calcu-
lated hepatic insulin clearance in these two groups
of animals was remarkably similar, being 1.629
0.143 ml!min in the controls and 1.632 0.26 ml!
mm in the uremics. There was no significant dif-
ference between the weights of the control and ure-
mic rat livers (11.2 0.7 vs. 11.3 0.6g).
Insulin degrading activity of liver and muscle ho-
mogenates. 251-iodo-insulin degrading activity in
homogenates of skeletal muscle and of liver ob-
tained from uremic and control animals is shown in
Table 1. Muscle (x 100,000g supernatant) insulin
degrading activity was reduced significantly by 12
to 17% in the uremic tissue as compared to controls.
No significant differences were seen in the insulin
degrading activity in the liver homogenates or sub-
cellular fractions thereof.
Insulin degradation by liver cell membranes. In-
sulin degradation by liver cell membranes was re-
duced significantly by 15% in the uremic animals as
compared with controls (Table 1). No significant
difference, however, in the apparent Km's for in-
sulin degradation by the two types of membranes
was seen, 2.7 x l0 M for the control vs. 2.1 x
10< tvl for the uremic membranes.
Insulin degradation by the intact epitrochlaris
muscle (Table 2). Epitrochiaris muscles from ure-
mic rats degraded two-thirds less insulin than did
muscles from control rats (P < 0.001). These results
are expressed as percentage degraded per milligram
of wet weight of tissue per 15 mm, but the same
level of significance was seen when the results were
expressed per milligram of protein. In other experi-
ments with these muscles, it was noticed that after
preincubation of the muscle, the preincubation buf-
fer acquired a significant amount of degrading activ-
ity whereas the degrading activity of the muscle it-
self decreased, possibly through leakage of en-
zymes from damaged muscle fibers. To avoid this
problem, we repeated the experiment with one of
each pair preincubated for is mm, during which
time most of the leakage occurred. Despite pre-
incubation, insulin degrading activity remained sig-
nificantly greater in the controls as compared with
uremics, whether preincubated or not. The degrad-
ing activity recovered in the supernatant was also
significantly greater in the control than it was in the
uremics.
Insulin binding by liver-cell membranes. Specific-
ity of '251-iodo-insulin binding to liver-cell mem-
branes obtained from urernic and control rats is
shown in Fig. 2. Maximal binding of '251-iodo-insulin
Table 1. Insulin degrading activityin muscle homogenate, liver homogenate, and liver cell membranes from control and uremic rats
No. per group Control Uremic P
Muscle homogenate°
>< l0gSupernatantexp. 1 5 118.4 4.5 98.4 0.8 <0.01
x 105g Supernatantexp. 2 6 98.6 3.5 87.2 2.1 <0.02
Liver homogenate° 6 135 8 137 10 NS
x 10gSupernatant 6 402 20 407 11 NS
x l0g Precipitate 6 18.8 2.0 22.4 2.0 NS
Liver plasma membranesh 7 16.97 0.28 14.5 0.32 <0.001
Weight of rats 9 412 8 422 9 NS
a lz51iodoinsulin (1 x lO M) was incubated with homogenate for 15 mm at 37° C. Activity is expressed as the percentage degraded
per milligram of protein SEM.
'21-insu1in(4 x 10l M) was incubated with liver plasma membranes (400 jig of protein per milliliter) for 15 mm at 37° C. Activity is
expressed as net trichloracetic acid soluble material SEM.
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Fig. 1. Left side: BUN in conirol (open bars) and uremic rats
(closed bars). Right side: Clearance of insulin by isolated in situ
perfused livers from control and uremic rats.
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Table 2. Insulin degradation by intact epitrochiaris muscles from control and uremic ratsa
Controls Uremics P
Muscle studied immediately 0.178 0.22 (8) 0.057 0.010 (6) <0.001
Preincubated muscle 0.126 0.013 (7) 0.045 0.006 (5) <0.001
Supernatant from preincubation 0.197 0.036 (7) 0.045 0.004 (5) <0.001
to liver-cell membranes from uremic animals was
11.6 0.4% as compared with 20.1 0.5% by
membranes from controls (P < 0.001). This dif-
ference was maintained over a wide range of insulin
concentration, 4 x 10 to 4 x 10-8 M/mg of pro-
tein.
A Scatchard plot of the binding data is shown in
Fig 3. These data suggest that the decrease in bind-
ing in uremia is due to a loss of receptors rather than
due to a change in affinity.
Discussion
It is well recognized that the kidney plays an im-
portant role in regulating plasma insulin levels in the
systemic circulation [1, 21]. Thus, the prolonged
half life of insulin in renal failure has generally been
regarded to be a consequence of the loss of this ma-
jor site of insulin removal, rather than a con-
sequence of the effect of uremia on other sites of
degradation. In support of this belief is the report
that in dogs, nephrectomy reduced the rate of insu-
lin removal from the systemic circulation, which
was not significantly altered by the advent of ure-
mia [22]. Similarly, Corvilain et al [5] noted that the
metabolic clearance rate of insulin was prolonged
in chronic renal failure patients, despite regular
hemodialysis, and they concluded that this derange-
ment in insulin metabolism was not due to an extra-
renal effect of uremia. In contrast, Hampers et a!
[6] reported an improvement in the rate of insulin
disappearance following hemodialysis and con-
cluded that the abnormality in insulin metabolism
was independent of renal tissue itself. Navalesi et
al [7], noting a small but significant increase in the
fractional catabolic rate of insulin in nephric but
not anephric patients on hemodialysis, concluded
that the impaired insulin catabolism was mainly
due to the loss of renal tissue and to a lesser extent
uremic inhibition of residual renal tissue.
To resolve these conflicting in vivo studies, the
present study was conducted with isolated tissues.
In the intact animal, depression of insulin degrada-
tion in one organ may possibly be compensated for
by increased degradation in another organ; thus, lo-
cal alterations in insulin degradation may not be de-
tected from measurements of insulin clearance from
the systemic circulation. We therefore used tissues
obtained from a uremic, partial-nephrectomized rat
model that was essentially the same as that de-
scribed by Soman and Felig [8]. They found that 4
weeks after partial nephrectomy, rats exhibit the
hyperglycemia, hyperinsulinemia, and hypergluca-
gonemia characteristic of carbohydrate intolerance
found in uremic man.
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Fig. 3. Scatchard analysis of insulin-binding data shown in Fig.
2. (.) = control; (X) = uremic.
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Fig. 2. Specific binding of I°5-iodo-insulin to liver-cell mem-
branes from control (0) and uremic (s)rats, and displacement by
unlabeled insulin.
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In the present study, despite the presence of sig-
nificant and prolonged renal insufficiency as mea-
sured by a BUN more than double the control val-
ue, the clearance of insulin by the isolated livers of
uremic rats was essentially the same as that of the
normal controls. This suggests that prolonged ure-
mia, as is the situation with acute uremia [23], does
not alter hepatic insulin uptake, an important nega-
tive finding, for not only does the liver remove ap-
proximately 40% of the insulin released into the
portal circulation [24, 25], but it also removes in-
sulin recirculating through the liver via the hepatic
artery and the mesenteric-portal circulation. Our
study does not exclude, however, the unlikely pos-
sibility that a factor present in uremic plasma, but
not in the perfusate, may produce a rapidly revers-
ible impairment of hepatic insulin metabolism. As
occurred with hepatic insulin clearance, degrada-
tion of '251-iodo-insulin by liver homogenates and
subcellular fractions thereof was not impaired by
uremia. Of particular importance was the finding
that binding and degradation of 1251-iodo-insulin by
uremic liver plasma membrane was reduced by 42
and 15%, respectively, when compared to the con-
trols. This suggests that alterations in binding and
degradation of insulin by the isolated liver plasma
membrane may not be reflected in the overall clear-
ance of insulin by the intact organ. Thus, the degree
of uremic depression of liver plasma membrane in-
sulin binding and degradation may not be suffi-
ciently severe to limit the overall hepatic insulin re-
moval process, which according to Terris and Stein-
er [27, 28] requires the binding of insulin to specific
receptor sites prior to its transfer to a degradative
site presumably within the liver cell.
Impaired insulin binding to liver plasma mem-
branes may have relevance to the insulin resistance
of uremia, for receptor binding appears to be a pre-
requisite before the hormone can exert an effect
[29]; there are, however, several situations in which
insulin binding and insulin action do not change in
parallel [30, 31]. For instance, insulin action on the
livers of diabetic rats is impaired [32] although bind-
ing to liver plasma membranes is increased in diabe-
tes [31]. Thus, it is possible that rate-limiting intra-
cellular events may play a role in the insulin resis-
tance of uremia. Glucagon may also play an
important role in impairing the glycemic response to
insulin, for in uremia there is an increased sensitivi-
ty to glucagon-induced hyperglycemia [26], which
presumably is a consequence of the increase in spe-
cific binding of glucagon to liver plasma mem-
branes, and in glucagon stimulation of adenyl-cy-
clase [8]. Although Soman and Felig [8] reported an
impairment in insulin binding to liver plasma mem-
branes comparable to that found in the present
study, they did not find the modest decrement in
membrane insulin degrading activity that we ob-
served.
Of particular importance is our finding that pro-
longed uremia significantly inhibits the degradation
of '251-iodo-insulin by intact isolated skeletal muscle
and by homogenates thereof. This observation is
similar to that of Mondon et al, who recently report-
ed that in rats acute uremia impaired insulin extrac-
tion by the isolated perfused hind limb [23]. Skeletal
muscle, although possessing only 21% of the de-
grading activity of liver and 43% of that of the kid-
ney per gram of tissue [4], is, because of its relative-
ly large mass and blood supply, perhaps as impor-
tant as the kidney in removing insulin from the
systemic circulation in rats [3, 23]. Thus, uremic de-
pression of insulin degradation in muscle may well
contribute to the prolonged insulin metabolic clear-
ance rate observed in chronic uremia.
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